High lithium levels increase the risk of side effects and intoxication, rendering patient monitoring even more important than for most other drugs. 4 Known long-term side effects of lithium treatment include the development of renal impairment and hypothyroidism. 5 For the early identification of patients with an increased risk of these side effects, regular measurement of biomarkers is considered standard of care.
Clinical practice guidelines (CPGs) provide guidance to health care professionals on patient monitoring. 6, 7 CPGs thus aim to bridge the gap between clinical research and clinical practice and to aid health care professionals in evidence-based decision making. 7 A good-quality guideline has been defined as providing: "the confidence that the potential biases inherent in guideline development have been addressed adequately and that the recommendations are both internally and externally valid (i.e., supported by evidence and applicable to target populations), and are feasible for practice". 8 In addition to the quality of the monitoring instructions in CPGs, it is important that monitoring instructions are easily identifiable and applicable for health care professionals. In a recent study from our research group, 74% of lithium prescribers stated that their monitoring policy was based on a guideline or institutional protocol. 9 To be applicable for health care professionals, it is important that guidelines address which and how clinical or biomarker parameters need to be monitored. Information is needed on when to start monitoring, when to stop monitoring, how frequently to monitor, what critical values are and how to respond to these values. 10, 11 CPGs should preferably include monitoring parameters that are specific, sensitive, accessible, affordable and applicable, and that provide early results to enable intervention. 12 Previous studies by our group revealed that instructions for monitoring in Summary of Product Characteristics of (psychotropic) drugs in general were often found to be too ambiguous to be applicable in clinical practice. 13, 14 The applicability of monitoring instructions for patients using lithium in CPGs for treatment of BD is still unknown.
The objective of this study was to assess the clarity of presentation and applicability of monitoring instructions for patients using lithium in CPGs for treatment of BD.
| ME THODS

| Identification and selection of clinical practice guidelines for BD
A search of CPGs on lithium treatment in BD was performed by exploring the literature databases Pubmed and Embase and the guideline-specific databases Guideline International Network (GIN) and National Guideline Clearinghouse (NGC) and by using a general search engine (Google). Furthermore, websites of chapters of the International Society for Bipolar Disorders (ISBD) were examined.
"lithium", "bipolar disorder" and "guideline" were used as search terms (Appendix 1). In addition to this literature search, prescribers of lithium participating in an online survey from our research group were requested to report guidelines that they use for monitoring of patients using lithium. 9 CPGs had to meet four criteria to be selected for assessment in the present study. First, a statement was required that the publication was indeed a guideline. Second, the scope of the CPG had to include sections on lithium treatment. Third, full texts needed to be available in the public domain. Finally, in order that the authors could understand it, the guideline needed to be written in English, Dutch or German. CPGs reporting solely on treatment during pregnancy and lactation or on toxicology were excluded.
As CPGs could have been revised, websites of publishing societies were assessed to select the most recent version. Retrieved articles were scanned for selection on the title and abstract and if needed full texts by two authors independently (MN and AB).
Inconsistencies between these authors were resolved by consulting a third author (EH) and were discussed until consensus was reached.
The authors were of the opinion that including all CPGs was unnecessary to achieve our aims and would even reduce the clarity of the results. To determine which CPGs were essential to be included, selected CPGs were discussed by three authors (MN, EH and AE).
The authors reviewed all CPGs and selected guidelines that were:
(a) from the major international societies; (b) from countries with a well-established CPG, and (c) from multiple continents. A maximum of one guideline per country was included.
| Clarity of presentation and applicability of CPGs
To assess the clarity of presentation and the applicability of the sections about monitoring instructions in CPGs, relevant parts of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument were used. 15 Two domains (domains 4 and 5), with in total seven items, of the AGREE II scoring tool were scored by two authors (MN and EH), consisting of the domains "clarity of presentation" and "applicability".
Clarity of presentation
I. The recommendations are specific and unambiguous.
II. The different options for management of the condition or health issues are clearly presented.
III. Key recommendations are easily identifiable.
Applicability
I. The guideline describes facilitators of and barriers to its application.
II. The guideline provides tools and/or advice on how the recommendations can be put into practice.
III. The potential resource implications of applying the recommendations have been considered.
IV. The guideline presents monitoring and/or auditing criteria.
Each item (e.g. 4.II) was scored based on a seven-point scale (rang- Third, the requirement for monitoring was classified as mandatory (e.g. "should be monitored"), recommended (e.g. "it is recommended to monitor") or in special circumstances (e.g. "monitor in the case of development of polyuria") based on the wording of the instructions.
Fourth, the applicability of monitoring instructions for patients using lithium was assessed according to the Systematic Information for Monitoring (SIM) score (Appendix 2). 13, 16 The SIM score rates monitoring instructions on six items of information, namely: "what to monitor", "when to start monitoring", "when to stop monitoring", "how frequently to monitor", "critical values of the parameter" and "how to respond". Each item of information yielded a score of 0 (information is not clearly described) or 1 (information is clearly described), leading to a total SIM score between 0 and 6. Monitoring instructions with a score of ≥3 were considered applicable.
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All monitoring instructions were collected and classified by two authors independently (MN and AB). Inconsistencies were discussed with a third author (EH) until consensus was reached.
| Data analysis
Instructions were divided into instructions on monitoring of lithium serum levels and instructions on monitoring of clinical and biomarker parameters. Instructions on lithium serum level monitoring were presented in more detail, providing information on target serum levels, point in time of blood sampling for serum level obtainment, frequency of monitoring, and factors requiring additional monitoring.
The number of CPGs scoring >70% of the maximum score was calculated for the domains "clarity of presentation" and "applicability".
For each CPG, the total number of monitoring instructions, the median SIM score (interquartile range) and the proportion of instructions considered applicable (SIM ≥3) were calculated. Furthermore, it was assessed which items were missing most often in monitoring instructions.
| RE SULTS
| Characteristics, clarity of presentation, and applicability of CPGs
Our search strategy resulted in a total of 31 CPGs after applying the exclusion and inclusion criteria, of which 16 were retrieved from Pubmed and ten from Embase, four were found using Google searches and one was found via the website of a chapter of the ISBD.
Some of these guidelines were available in multiple literature data- The clarity of presentation in most CPGs was good according to the assessment questions of the AGREE II scoring tool (Table 1) .
Six out of the nine guidelines scored >70% of the maximum score.
Most recommendations were specific and unambiguous (overall mean percentage of maximum score: 69%). Different options for management of the condition or health issue were clearly presented (67%). As many CPGs aimed to highlight certain recommendations by using tables, boxes, figures or clear headings, key recommendations were easy to identify (67%). In particular, the Dutch and German guidelines clearly presented monitoring instructions and can be used as examples to improve the clarity of presentation of CPGs.
Scores for the applicability of CPGs were lower compared to the clarity of presentation, with only one guideline scoring >70% of the maximum score. In particular, information on the resource implications of monitoring was scarce (31%). Also, information on facilitators of and barriers to monitoring was limited (35%). Tools and advice on how monitoring can be performed in clinical practice were occasionally provided (43%). Monitoring and auditing criteria were present in almost half of CPGs (48%), but could be elaborated. The National Collaborating Centre for Mental Health (NICE) guideline scored highest on total applicability according to the AGREE II scoring tool (88% of the maximum score).
| Lithium monitoring instructions
In every CPG, instructions for monitoring of the lithium serum concentration were found, which are presented in Table 2 Often special circumstances were mentioned requiring additional monitoring. Lithium monitoring instructions were determined as applicable in all guidelines with a SIM score of 4 or 5.
| Monitoring of additional physical and laboratory parameters before and during lithium use
In total, 247 monitoring instructions were found for monitoring of patients using lithium in all CPGs for BD with an average of 27 instructions (range 4-61) per CPG. The content of monitoring instructions varied between guidelines (Table 3) .
Parameters of renal and thyroid function needed to be monitored according to all guidelines, although differences were noticeable with regard to specific biomarkers. Besides renal and thyroid function, monitoring of body weight, blood pressure, electrolytes, hepatic function and full blood count was most frequently mentioned. A pregnancy test for baseline monitoring of female patients was mentioned in many CPGs.
Most instructions were formulated in such a way that monitoring was mandatory (n = 178, 72%), while in others monitoring was rec- Seventy-seven percent of all monitoring instructions were applicable in clinical practice (Table 4) . Most instructions 1, during (hypo)mania; 2, whenever toxicity symptoms are present or suspected; 3, if the serum level is near the upper target level; 4, in older patients; 5, in patients with (suspected) noncompliance in terms of taking the drug; 6, when the patient is likely to experience dehydration or in the case of fluid loss; 7, whenever the clinical status changes, physical health issues appear or adverse drug events emerge; 8, after start, stop or dosage change of medication interacting with lithium; 9, in patients who have poor symptom control or signs of ineffectiveness; 10, in patients with or who are at risk of impaired renal or thyroid function, raised calcium levels or other complications or comorbid disorders. On indication or for specific patient populations; black is mandatory and white is recommended or other.
TA B L E 3 Biomarker monitoring instructions in clinical practice guidelines for bipolar disorder
/L A A Pulse A L a L a A A A A a /L ECG L a A a A L a L a L a A A a A a A Pregnancy test L A a A a A a A a A a A a L Renal function L L A L A L A A a /L A a /L A a /L L L Creatinine L A A L A L A L A A a /L L L eGFR A L L L L L A A a /L L L L L Urea L A L A L A A a /L A L Albumin A A a /L Thyroid function L L L A A L L A L A A a /L A A a /L L L TSH A L L L L L L A A a /L L L T4 L A a A a T3 L Anti-thyroid autoantibodies A a A a A Parathyroid function PTH L a L a A a A a L L Electrolytes A A L A L A L A A a /L A A a /L Sodium L L L a L a A A a /L Potassium L a L a L L A A a /L Calcium L L L L L L L L A A a /L L L
Metabolic parameters (Fasting) glucose
TA B L E 3 (Continued)
provided information on what to monitor (199/247, 81%), when to start monitoring (203/247, 82%) and the monitoring frequency 
| D ISCUSS I ON
Most CPGs presented monitoring instructions clearly. Instructions could be easily found as guidelines often presented monitoring instructions in boxes, figures, or tables. Still, the applicability of CPGs on monitoring could be improved. A previous study assessing the management of lithium intoxication found the applicability of guidelines to be poor. 32 Limited applicability may be a concern not only for guidelines for BD or lithium treatment; a review of guideline quality found scores for the applicability of guidelines from a wide range of health care topics to be poor in general. 7 Scores for clarity of presentation were relatively low compared to guidelines included in that review, although these may not be completely comparable as our study focused on the clarity of patient monitoring instructions rather than that of the overall guideline. 7 For future development of (updates of) guidelines, applying the AGREE II tool to the guideline and obtaining an SIM score for the monitoring instructions before publishing may help to identify items requiring additional refinement. According to our assessment, a more extensive description of resource implications, facilitators, and tools could be given by describing monitoring costs and providing checklists.
CPGs contained variable instructions for monitoring of patients using lithium. Instructions on monitoring of lithium serum levels were present in all guidelines, although target levels and the frequency of monitoring varied between guidelines. Additional physical and laboratory monitoring parameters concerned renal and thyroid function, with varying additional parameters mentioned among CPGs.
An overview of monitoring instructions for lithium serum levels and renal and endocrine tests was previously provided by Malhi et al. 33 In the present study, an overview in Table 3 is given of additional monitoring parameters, providing insight into the variability of patient monitoring in guidelines.
The validity of monitoring parameters for patients using lithium presented in guidelines remains uncertain. The results demonstrate the lack of consensus in the field on monitoring of a medication that has been used for treatment of BD for a long time. To assess the validity, a literature review is recommended, although evidence for an optimal monitoring schedule may be lacking. 34 Research on the effectiveness and limitations of patient monitoring may help to establish more evidence-based instructions. The overview in Tables 2   and 3 can be used to help to assess differences between guidelines and inspire professional organizations or researchers to investigate which parameters should be assessed when monitoring patients using lithium. Furthermore, including information on critical values and how to respond to deviating values may further improve applicability for clinical practice. 35 The CPG of the APA included a preface stating that the guideline was "not intended to be construed or to serve as a standard of medical care", but should be considered as a guideline only. 17 Guidelines should indeed be used to "guide" health care professionals, and it should always be assessed whether the monitoring instructions are applicable to a specific patient. For many monitoring instructions, research evidence on how to adequately monitor patients is missing. 34 Studies to define the number of patients required to be monitored to obtain adequate power for data that could be used to improve the efficacy or to prevent side effects are needed. 36 Ideally, these instructions should be personalized, as some parameters only need to be monitored within specific patient populations. 37 The scope of guidelines differed; some were focused on BD, on and country-specific factors such as availability of resources for monitoring.
CPGs were rigorously assessed, resulting in generation of recommendations to improve the quality of CPGs and monitoring instructions for patients using lithium.
A difficulty in rating CPGs was experienced during analysis using the AGREE II tool, especially regarding the clarity of presentation.
The application of scores based on the AGREE II tool remained partly subjective, although differences between assessors were discussed until consensus was reached. Differences noticed between the assessors were only minor, and therefore scores were considered accurate.
Some items included in the AGREE II score or SIM scores may be more important for applicability in clinical practice compared to other items. No additional weight was given to individual items of the AGREE II tool or SIM score, as we did not intend to assess "the best CPG", but to provide recommendations for improvement.
If CPGs are improved, the quality of patient monitoring by health care professionals may improve in clinical practice, as many health care professionals state that they use guidelines for monitoring. 9 Thereby, the CPGs will better "guide" health care professionals.
In conclusion, improvement of the applicability of CPGs is needed, and can be achieved by describing the resource implications of monitoring and the facilitators of and barriers to monitoring. In addition, information on critical values and how to respond to aberrant parameters in monitoring instructions is needed. With such improvements, CPGs may better aid health care professionals regarding how to monitor patients using lithium.
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